Advertisement

MGMT Reduction Boosts TMZ Sensitivity in HEK293T Cells

May, 05, 2024 | Brain Cancer

KEY TAKEAWAYS

  • The study aimed to evaluate the impact of O6-MGMT activity on TMZ effectiveness in GBM treatment.
  • The study provided evidence for using CRISPR-based gene suppression to overcome TMZ resistance and enhance its effectiveness in GBM.

Surgical resection followed by radiotherapy, along with concurrent and adjuvant chemotherapy using Temozolomide (TMZ), is the standard of care for patients with glioblastoma (GBM), the most prevalent and aggressive form of brain cancer. The efficacy of TMZ hinges on O6-methylguanine DNA methyltransferase (MGMT) activity, which repairs alkyl adducts at the DNA level, mitigating TMZ’s toxic effects.

Yasamin Yousefi and the team aimed to investigate strategies for enhancing the effectiveness of TMZ chemotherapy in GBM treatment, particularly by targeting O6-MGMT activity.

The study utilized fusions of catalytically-inactive Cas9 (dCas9) to DNA methyltransferases (dCas9-DNMT3A) to selectively downregulate MGMT transcription by inducing methylation at the MGMT promoter and K-M enhancer.

The results revealed a substantial decrease in MGMT expression, which correlates with increased sensitivity to TMZ in the HEK293T cell line.

The study provided evidence supporting the feasibility of using CRISPR-based gene suppression to overcome TMZ resistance and augment its cytotoxic effects in glioblastoma tumor cells.

No funding information was available.

Source: https://link.springer.com/article/10.1007/s11060-024-04708-0

Yousefi, Y., Nejati, R., Eslahi, A. et al. (2024). “Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT).” J Neurooncol (2024). https://doi.org/10.1007/s11060-024-04708-0

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –

Advertisement

LATEST

Advertisement

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy